When employing immunotherapies, oncologists must be vigilant in spotting any adverse events and calling in their colleagues, like dermatologists or pulmonologists, to help manage these toxicities, according to Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco.
When employing immunotherapies, oncologists must be vigilant in spotting any adverse events and calling in their colleagues, like dermatologists or pulmonologists, to help manage these toxicities, according to Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco.
Transcript (slightly modified)
What are some of the toxicity concerns with immunotherapy and how can they be managed?
One of the exciting things about oncology is we’re such a multidisciplinary field. We’re really used to working in tumor boards, medical oncology, surgical oncology, pathology, radiology. These drugs are really forcing us to look even further abroad. We’re really looking at working with our endocrinologists, our pulmonologists, our rheumatologists, because some of these immune adverse events [AEs] are really coming to the fore, things that oncologists haven’t had to deal with medically.
I think there are 2 questions. One is, for patient selection for these agents, can you give these drugs to patients who have autoimmune disease, and we’re trying to suss that out. Folks who have long-standing hypothyroidism, not a problem. Patients with active ulcerative colitis, certainly we can’t use them.
But then of course the question is, after they’ve been treated, how do we handle that? First and foremost, it’s just recognition, anticipation and recognition. Certainly we do thyroid function tests very regularly throughout the course of treatment. We’re very attuned to changes in oxygenation that may portend pneumonitis, and then we’re really quick to, when we see those kind of changes, engaging our colleagues. So if there’s a rash, we have dermatologists who are savvy about these and help us to manage them.
Really, the name of the game is making sure we handle these AEs so that patients who are benefiting can continue to benefit and not have the morbidity or even mortality of some of these side effects.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care
March 13th 2025Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More